Yang Kechun, Jin Guozhang, Wu Jie
Division of Neurology, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ 85013, USA.
Curr Neuropharmacol. 2007 Dec;5(4):289-94. doi: 10.2174/157015907782793649.
(-)-Stepholidine (SPD), a natural product isolated from the Chinese herb Stephania, possesses dopamine (DA) D1 partial agonistic and D2 antagonistic properties in the nigrostriatal and mesocorticolimbic DAergic pathways. These unique dual effects have suggested that SPD can effectively restore previously imbalanced functional linkage between D1 and D2 receptors under schizophrenic conditions, in which, SPD improves both the negative and positive symptoms of schizophrenia. SPD also relieves the motor symptoms of Parkinson's disease (PD) when co-administered with Levodopa. Furthermore, SPD exhibits neuroprotective effects through an antioxidative mechanism and slows down the progression of neuronal degeneration in the substantia nigra (SN) of PD patients and/or animal models. Therefore, SPD is a novel, natural compound with potentially therapeutic roles in the treatment of schizophrenia and/or PD.
(-)-千金藤啶碱(SPD)是从中药千金藤中分离出的一种天然产物,在黑质纹状体和中脑皮质边缘多巴胺能通路中具有多巴胺(DA)D1部分激动和D2拮抗特性。这些独特的双重作用表明,SPD可以有效恢复精神分裂症状态下D1和D2受体之间先前失衡的功能联系,其中,SPD可改善精神分裂症的阴性和阳性症状。与左旋多巴联合使用时,SPD还可缓解帕金森病(PD)的运动症状。此外,SPD通过抗氧化机制发挥神经保护作用,并减缓PD患者和/或动物模型黑质(SN)中神经元变性的进展。因此,SPD是一种新型天然化合物,在治疗精神分裂症和/或PD方面具有潜在的治疗作用。